Amyloid-Targeting Antibodies

Mechanism

Related News

New Research Highlights Combination Therapy and Molecular Pathways in Alzheimer's Disease

Two recent studies advance Alzheimer's research: one finds combining anti-amyloid antibodies with natural compounds improves efficacy and safety, while another maps a molecular cascade that could reveal new therapeutic targets. The combination therapy study used aducanumab, lecanemab, resveratrol, and curcumin. The molecular study identified gene expression networks and proposed a two-stage disease model.

Experts dispute Cochrane review on anti-amyloid Alzheimer’s drugs

A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.